
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
As we continue to debate and search for a common treatment for these two diseases, physicians should continue to treat these as two different entities as we have in the past.





